These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 21595894)

  • 1. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
    Chan TW; Pollak M; Huynh H
    Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
    Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
    Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
    Chen J; Hou R; Zhang X; Ye Y; Wang Y; Tian J
    PLoS One; 2014; 9(3):e91245. PubMed ID: 24618835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk.
    Klotz DM; Hewitt SC; Ciana P; Raviscioni M; Lindzey JK; Foley J; Maggi A; DiAugustine RP; Korach KS
    J Biol Chem; 2002 Mar; 277(10):8531-7. PubMed ID: 11751931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells.
    Li M; Chiu JF; Gagne J; Fukagawa NK
    J Cell Physiol; 2008 Nov; 217(2):377-87. PubMed ID: 18615585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
    Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
    Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
    Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
    Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-1 receptor-mediated inhibition of A-type K(+) current induces sensory neuronal hyperexcitability through the phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 pathways, independently of Akt.
    Wang H; Qin J; Gong S; Feng B; Zhang Y; Tao J
    Endocrinology; 2014 Jan; 155(1):168-79. PubMed ID: 24080365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells.
    Dhar K; Banerjee S; Dhar G; Sengupta K; Banerjee SK
    Cancer Res; 2007 Feb; 67(4):1520-6. PubMed ID: 17308090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.
    Juncker-Jensen A; Lykkesfeldt AE; Worm J; Ralfkiaer U; Espelund U; Jepsen JS
    Growth Horm IGF Res; 2006 Aug; 16(4):224-39. PubMed ID: 16893667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
    Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
    Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.